MCE 的所有產品僅用作科學研究或藥證申報,，我們不為任何個人用途提供產品和服務,。

Etrasimod

CAS No. : 1206123-37-6

產品活性：Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P₁) receptor with an IC₅₀ value of 1.88 nM in CHO cells.

研究領域：GPCR/G Protein

作用靶點：LPL Receptor

In Vitro: APD334 is a structurally novel, selective, functional antagonist of S1P₁. In CHO cells expressing HA tagged S1P₁, APD334 is found to have an IC₅₀ value of 1.88 nM. Moderate agonism at human S1P₄ and S1P₅ is observed but is reduced relative to S1P₁, both in terms of potency and efficacy. APD334 is devoid of any agonism or antagonism at human S1P₂ and S1P₃. APD334 achieves good central exposure following oral dosing and possesses a favorable pharmacokinetic profile in multiple preclinical species. S1P₁ activity is maintained in mice (EC₅₀=0.44 nM), rats (EC₅₀=0.32 nM), dogs (EC₅₀=0.34 nM) and monkeys (EC₅₀=0.32 nM).

In Vivo: APD334 has a relatively low systemic clearance (<4% of hepatic blood flow) and high C_max across all species. In both dog and monkey a significant decrease in volume of distribution (Vss) is observed relative to rodent. Oral bioavailability is in the range of 40–100%, and the terminal phase half-life varied from 6 h in monkey, to as long as 29 h in dog. Rat and monkey t_1/2 values for siponimod (another S1P1 modulator currently in human trials) have been disclosed and are 6 and 19 h, respectively.

相關產品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  Rare Diseases Drug Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  BMS-986020 sodium  |  ONO-0300302  |  BMS-986278  |  NAEPA  |  Sphingosine-1-phosphate-d₇  |  S1P1 agonist III  |  S1PR1 modulator 1  |  LPA2 antagonist 2  |  Radioprotectin-1  |  S1PR1 agonist 1  |  TC-SP 14  |  CYM50358  |  W146  |  Udifitimod  |  CRT0273750  |  Ki16425  |  ONO-9780307  |  CS-2100  |  Fingolimod phosphate-d₄  |  CAY10444  |  ONO-0740556  |  NIBR0213  |  CYM50260  |  ASP-4058  |  FTY720 (S)-Phosphate  |  Sonepcizumab  |  TAK-615  |  GSK2018682  |  Mocravimod hydrochloride

熱門產品線：重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物,；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽,，常用試劑盒 ，更有 PROTAC,、ADC 等特色產品,，廣泛應用于新藥研發(fā)、生命科學等科研項目,；
•   提供虛擬篩選,，離子通道篩選，代謝組學分析檢測分析,，藥物篩選等專業(yè)技術服務,；
•   設有專業(yè)的實驗中心和嚴格的質控、驗證體系,；
•   提供 LC/MS,、NMR、HPLC,、手性分析、元素分析等各項質檢報告,，確保產品的高純度,、高品質；
•   產品的生物活性多經各國客戶實驗驗證,；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果,；
•   專業(yè)團隊跟蹤最新的制藥及生命科學研究進展，為您提供*新的活性化合物,；
•   與世界各大制藥公司及著名科研機構建立了長期的合作,。